Assessment to Identify Predictors of 2-Hour Pain Freedom among Patients Enrolled in 2 Phase 3 Studies of Lasmiditan for Acute Treatment of Migraine

被引：0
|
作者：
Vargas, Bert B. [1 ]
Magis, Delphine [2 ]
Doty, Erin [3 ]
Ruff, Dustin [3 ]
Vasudev, Raghavendra [3 ]
Krege, John H. [3 ]
Hake, Ann [3 ,4 ]
机构：
[1] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[2] Univ Dept Neurol, Dallas, TX USA
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
[4] Indiana Univ, Sch Med, Bloomington, IN 47405 USA
来源：
NEUROLOGY | 2020年 / 94卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
1763
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Assessment to Identify Predictors of 2-hour Pain Freedom Among Patients Enrolled in Two Phase 3 Studies of Lasmiditan for Acute Treatment of Migraine
    Vargas, Bert B.
    Magis, Delphine
    Doty, Erin
    Ruff, Dustin
    Vasudev, Raghavendra
    Krege, John H.
    Hake, Ann
    [J]. CEPHALALGIA, 2019, 39 : 185 - 186
  • [2] An Optional Second Dose of Ubrogepant Is Effective in Achieving 2-Hour Pain Freedom in the Acute Treatment of Migraine
    Ailani, J.
    Blumenfeld, A. M.
    Klein, B.
    Finnegan, M.
    Severt, L.
    Liu, C.
    Trugman, J. M.
    [J]. HEADACHE, 2019, 59 : 98 - 98
  • [3] An Optional Second Dose of Ubrogepant is Effective in Achieving 2-Hour Pain Freedom in the Acute Treatment of Migraine
    Ailani, Jessica
    Blumenfeld, Andrew
    Klein, Bradley
    Finnegan, Michelle
    Severt, Lawrence
    Liu, Chengcheng
    Trugman, Joel
    [J]. NEUROLOGY, 2020, 94 (15)
  • [4] Evaluation of 2-Hour Post-Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult-to-Treat Migraine Attacks
    Tepper, Stewart J.
    Vasudeva, Raghavendra
    Krege, John H.
    Rathmann, Suchitrita S.
    Doty, Erin
    Vargas, Bert B.
    Magis, Delphine
    Komori, Mika
    [J]. HEADACHE, 2020, 60 (08): : 1601 - 1615
  • [5] Phase 3 Studies (SAMURAI, SPARTAN) of Lasmiditan Compared to Placebo for Acute Treatment of Migraine
    Wietecha, L.
    Kuca, B.
    Asafu-Adjei, J.
    Aurora, S.
    [J]. HEADACHE, 2018, 58 : 73 - 73
  • [6] Phase 3 studies (SAMURAI, SPARTAN) of lasmiditan compared to placebo for acute treatment of migraine
    Wietecha, Linda A.
    Kuca, Bernice
    Asafu-Adjei, Josephine
    Aurora, Sheena K.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [7] Phase 3 Studies (SAMURAI, SPARTAN) of Lasmiditan Compared to Placebo for Acute Treatment of Migraine
    Wietecha, Linda A.
    Kuca, Bernice
    Asafu-Adjei, Josephine
    Aurora, Sheena K.
    [J]. NEUROLOGY, 2018, 90
  • [8] Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients
    Sakai, Fumihiko
    Takeshima, Takao
    Homma, Gosuke
    Tanji, Yuka
    Katagiri, Hideaki
    Komori, Mika
    [J]. HEADACHE, 2021, 61 (05): : 755 - 765
  • [9] Safety Findings from the Phase 3 Studies (SAMURAI, SPARTAN) of Lasmiditan for Acute Treatment of Migraine
    Krege, John H.
    Liffick, Emily
    Doty, Erin G.
    Dowsett, Sherie A.
    Wang, Jia Ning
    Buchanan, Andrew S.
    [J]. NEUROLOGY, 2019, 92 (15)
  • [10] Neck Pain or Headache: Which Is the Better Predictor of 2-Hour Pain-Free Following Migraine Treatment?
    Ford, Sutapa
    Calhoun, Anne
    Nie, Yonghong
    Truong, Young
    Finkel, Alan
    [J]. NEUROLOGY, 2009, 72 (11) : A91 - A91
12345